APC 2059

Drug Profile

APC 2059

Latest Information Update: 02 Jul 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer; Celera Genomics Group
  • Developer Celera Genomics Group
  • Class Anti-inflammatories; Dioxoles; Guanidines; Small molecules
  • Mechanism of Action Peptide hydrolase inhibitors; Tryptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammatory bowel diseases; Psoriasis; Ulcerative colitis

Most Recent Events

  • 06 Jun 2004 Discontinued - Phase-I for Inflammatory bowel disease in USA (IV-injection)
  • 06 Jun 2004 Discontinued - Phase-II for Ulcerative colitis in USA (SC)
  • 30 Mar 2001 Clinical trials of APC 2059 in asthma postponed until 2002
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top